1828. Interim Analysis of an Interferon (IFN)- And Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 In Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients
Session: Oral Abstract Session: Hepatitis C
Saturday, October 5, 2013: 2:45 PM
Room: The Moscone Center: 250-262
Background: The IFN- and RBV-free regimen of DCV (NS5A inhibitor), ASV (protease inhibitor) and BMS-791325 (non-nucleoside NS5B inhibitor, 75mg BID) achieved sustained virologic response (SVR4, SVR12) >90% in treatment-naïve, hepatitis C virus (HCV) genotype (GT) 1 patients. We evaluated this regimen using two BMS-791325 doses (75 vs 150 mg BID).

Methods: HCV GT1, treatment-naïve, non-cirrhotic patients (N=32) were randomized 1:1 to DCV 60mg QD, ASV 200mg BID, and BMS-791325 75mg BID for 24 (Group 1) or 12 (Group 2) weeks. Subsequently, 34 additional patients were randomized to DCV, ASV, and BMS-791325 150mg BID for 24 (Group 3) or 12 (Group 4) weeks. The primary end point was HCV RNA <25 IU/mL at 12 weeks post-treatment (SVR12). Interim results are presented.

Results: Patients were mainly GT1a (74%), white (79%), and IL28Bnon-CC (70%). 64/66 patients had HCV RNA <25 IU/mL by Week 4 (Table). There was no difference in virologic response between 12 and 24 weeks of treatment. Overall, patients achieved SVR4 92% (46/50), SVR12 94% (30/32), and SVR24 94% (15/16). No patient discontinued for adverse events (AEs) related to DCV+ASV+BMS-791325. Most common AEs (≥10% total) were headache, asthenia, and gastrointestinal. Two serious AEs were reported, both unrelated to DCV+ASV+BMS-791325. No hepatotoxicity or Grade 3/4 elevations of ALT/AST or bilirubin were reported.

Conclusion: DCV+ASV+BMS-791325 achieved high rates of SVR4, SVR12, and SVR24 in treatment-naive GT1 patients, characterized by GT1a and IL28Bnon-CC. This regimen was well tolerated with no apparent safety signals. Expansion of the current study is underway to better define the efficacy and safety of this regimen.

Virologic Response During and After Treatment

BMS-791325 Dose

 

75 mg

 

150 mg

Duration

 

24 weeks

 

12 weeks

 

24 weeks

 

12 weeks

Group

 

1 (N=16)

 

2 (N=16)

 

3 (N=16)

 

4 (N=18)

HCV RNA <25IU/mL, n(%)

 

 

 

 

 

 

 

 

     Week 4

 

16(100)

 

16(100)

 

16(100)

 

16(89)a

     EOT/Last on-treatment

 

15(94)b

 

16(100)

 

-

 

17(94)c

     SVR4

 

15(94)b

 

15(94)d

 

-

 

16(89)c,e

     SVR12

 

15(94)b

 

15(94)d

 

-

 

-

     SVR24

 

-

 

15(94)f

 

-

 

-

Virologic breakthrough, n(%)

 

0

 

0

 

1(7)

 

1(6)

Relapse, n(%)

 

0

 

0

 

-

 

1(6)

aOne patient with isolated HCV RNA of 43 IU/mL, one patient missing; b Patient withdrew consent; cOne viral breakthrough; dOne missing; eOne relapse; fA second patient missing.

Gregory T. Everson1, Karen D. Sims2, Maribel Rodriguez-Torres, MD3, Christophe Hézode4, Eric Lawitz5, Marc Bourlière6, Veronique Loustaud-Ratti7, Vinod Rustgi8, Howard Schwartz9, Harvey Tatum10, Patrick Marcellin11, Stanislas Pol12, Paul J. Thuluvath13, Timothy Eley, PhD2, Xiaodong Wang2, Shu-Pang Huang14, Fiona Mcphee15, Megan Wind-Rotolo14, Ellen Chung2, Claudio Pasquinelli2, Dennis M. Grasela2 and David F. Gardiner2, (1)University of Colorado Denver, Aurora, CO, (2)Bristol-Myers Squibb, Hopewell, NJ, (3)Gastroenterology, Fundacion de Investigacion, Rio Piedras, PR, (4)CHU Henri Mondor, Service d’Hépato-Gastroentérologie, Créteil, France, (5)Alamo Medical Research, San Antonio, TX, (6)Hôpital Saint Joseph, Service d’Hépato-Gastroentérologie, Marseille, France, (7)University Hospital of Limoges, Limoges, France, (8)Metropolitan Research, Arlington, VA, (9)Miami Research Associates, South Miami, FL, (10)Options Health Research, Tulsa, OK, (11)Hôpital Beaujon, Clichy, France, (12)Université Paris Descartes, INSERM U1610 and Liver Unit, Hôpital Cochin, Paris, France, (13)Mercy Medical Center, Baltimore, MD, (14)Bristol-Myers Squibb, Princeton, NJ, (15)Bristol-Myers Squibb, Wallingford, CT

Disclosures:

G. T. Everson, Bristol-Myers Squibb: Investigator, Research support

K. D. Sims, Bristol-Myers Squibb: Employee, Salary

M. Rodriguez-Torres, Bristol-Myers Squibb: Investigator, Research support

C. Hézode, Bristol-Myers Squibb: Investigator, Research support

E. Lawitz, Bristol-Myers Squibb: Investigator, Research support

M. Bourlière, Bristol-Myers Squibb: Investigator, Research support

V. Loustaud-Ratti, Bristol-Myers Squibb: Investigator, Research support

V. Rustgi, Bristol-Myers Squibb: Investigator, Research support

H. Schwartz, Bristol-Myers Squibb: Investigator, Research support

H. Tatum, Bristol-Myers Squibb: Investigator, Research support

P. Marcellin, Bristol-Myers Squibb: Investigator, Research support

S. Pol, Bristol-Myers Squibb: Investigator, Research support

P. J. Thuluvath, Bristol-Myers Squibb: Investigator, Research support

T. Eley, Bristol-Myers Squibb: Employee, Salary

X. Wang, Bristol-Myers Squibb: Employee, Salary

S. P. Huang, Shu-Pang Huang: Employee, Salary

F. Mcphee, Bristol-Myers Squibb: Employee, Salary

M. Wind-Rotolo, Bristol-Myers Squibb: Employee, Salary

E. Chung, Bristol-Myers Squibb: Employee, Salary

C. Pasquinelli, Bristol-Myers Squibb: Employee, Salary

D. M. Grasela, Bristol-Myers Squibb: Employee, Salary

D. F. Gardiner, Bristol-Myers Squibb: Employee, Salary

See more of: Hepatitis C
See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.